Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters











Database
Language
Publication year range
1.
Cytokine ; 6(3): 310-7, 1994 May.
Article in English | MEDLINE | ID: mdl-8054488

ABSTRACT

The anti-tumour properties of interleukin 1 beta (IL-1 beta) were examined using an intradermal B16 murine melanoma surgical model. B16 cells were injected intradermally on the right ventral side and surgery was performed on days 10-20 to remove the primary tumours. IL-1 beta or vehicle was administered prior to surgery for 5-7 consecutive days. In mice which received only injections of vehicle, survival ranged between 0 and 30% when measured on day 120 after implantation of B16 cells. Mice died of metastases and growth of B16 cells in the thoracic lymph nodes. When mice without metastases were rechallenged with viable B16 cells, only one out of 22 mice (5%) failed to develop tumours. No significant immunity to B16 cells was detected in this group of mice. In contrast, in mice which received injections of IL-1 beta, survival ranged between 70-100% on day 120 after implantation of B16 cells. When IL-1 beta treated mice were rechallenged with viable B16 cells on day 120, 20 out of 32 (63%) mice failed to develop B16 tumours suggesting that some of these mice had immunity to B16 melanoma cells. Moreover, mice with immunity to B16 cells did develop tumours when injected with another syngeneic tumour, MCA 105. In vitro specific immune responses were also demonstrated in spleen cells and sera from mice treated with IL-1 beta, but not in the spleen cells or sera of mice that received only vehicle.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Antibody Formation/drug effects , Interleukin-1/therapeutic use , Melanoma, Experimental/immunology , Melanoma, Experimental/therapy , T-Lymphocytes/immunology , Animals , Cytotoxicity, Immunologic , Female , Lymphatic Metastasis , Melanoma, Experimental/pathology , Mice , Mice, Inbred C57BL , Neoplasm Metastasis , Recombinant Proteins/therapeutic use , Spleen/immunology
2.
Yale J Biol Med ; 61(2): 115-22, 1988.
Article in English | MEDLINE | ID: mdl-3407210

ABSTRACT

Psychosis was present in 29 percent of cocaine-disordered patients hospitalized in 1985 during an epidemic of freebase cocaine abuse in the Bahamas. Record reviews revealed that a variety of psychotic phenomenologic patterns were present. Prior major mental disorders and increased dosage of cocaine were more common among psychotic than non-psychotic patients. Violent behavior was common among cocaine patients, especially those with psychosis. We conclude that freebase cocaine psychosis is neither rare nor benign.


Subject(s)
Cocaine , Psychoses, Substance-Induced/epidemiology , Substance-Related Disorders/complications , Adult , Bahamas , Dangerous Behavior , Delusions/epidemiology , Delusions/etiology , Female , Humans , Male , Psychoses, Substance-Induced/etiology , Socioeconomic Factors
SELECTION OF CITATIONS
SEARCH DETAIL